About Robbins LLP : A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LL have been dedicated to helping shareholders recover losses, improve corporate governance ...

The law firm of Kessler Topaz Meltzer & Check, LLP ( informs investors that a securities class action lawsuit has been filed against Sarepta Therapeutics, Inc. ("Sarepta") ( NASDAQ: SRPT) on behalf ...

Sarepta Therapeutics shares sank to their lowest level in nine years Monday after a second patient taking its Elevidys drug ...

The FDA is investigating two deaths in non-ambulatory Duchenne muscular dystrophy patients who received a Sarepta gene ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is one of the Massive Sell-Offs: These 10 Stocks Shockingly Nosedived. Sarepta ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards ...

Sarepta is facing a shareholder lawsuit over ELEVIDYS-related deaths. Robbins LLP cites safety risks and stock losses.

Sarepta Therapeutics Inc. misled investors about the safety and prospects for one of its Duchenne muscular dystrophy ...

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $72.34, a high estimate of $183.00, and a low estimate of $10.00. Highlighting a 37.16% decrease, the current ...

Review which funds and institutions currently hold Sarepta Therapeutics Inc (SRPT:XNAS) stock for ownership information.

Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT) investors of ...